Clinical TrialID 5287
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors
NCT02496949
Solid Tumors
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 5287
- Evidence Id
- 5287
- Core Evidence Id
- 5287
- Source Clinical Trial Id
- 5273
- Herb2 Clinical Trial Id
- HBCT005273
- Nct Id
- NCT02496949
- Title
- A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study Result
- No
- Study Condition
- Solid Tumors
- Study Type
- Interventional
- Study Design
- Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: Icaritin
- Intervention Allocation
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 28
- Outcome Measure
- The number of patients reported adverse events, 1-2 year
- Sponsor Collaborator
- Chinese Academy of Medical Sciences|Beijing Shenogen Biomedical Co., Ltd
- Funded By
- OTHER
- Location
- Cancer institute & hospital, chinese academy of medical sciences, Beijing, Beijing, 100021, China
- Other Id
- TG1114ICR
- Start Date
- 2011-11
- Primary Completion Date
- 2013-05
- Completion Date
- 2013-08
- First Posted
- 2015-07-14
- Results First Posted
- Last Update Posted
- 2015-07-14
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT02496949
- Title Cn
- Title En
- A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors
- Bilingual Status
- semi_complete